Ed Cannon, Ph.D. Dr. Cannon joined in December 2004 as President and CEO. Previously, he was the founding President and CEO of Elixir Pharmaceuticals and served as a director of Elixir, positions he held from April 2001 to March 2004. Prior to Elixir, he was a founder, director, President Therapeutics Division, and executive vice president, for Dyax Corp., a public biotechnology company engaged in developing biotherapeutic products. Dyax was formed in 1995 through the merger of Biotage, Inc. and Protein Engineering Corp., where Dr. Cannon was a director and CEO. Previously, he was a founder, director and CSO of Hygeia Sciences, the leading developer of monoclonal antibody-based home diagnostic products. He trained in molecular immunology at Harvard Medical School and has held faculty positions at Brandeis University and University of Massachusetts Medical School.
Nils Bergenhem, Ph.D. Dr. Bergenhem joined AdipoGenix in June 2005 as Chief Scientific Officer. He has over 16 years of experience in the metabolic disease arena, which includes managing drug discovery and development. Prior to joining AdipoGenix he was Vice President of Research at the Institute for Diabetes Discovery (IDD), where he managed the development of small molecule drugs for the treatment of diabetes, diabetic complications, and obesity. Before joining IDD, Dr. Bergenhem held the position as Director for Diabetes Research at OSI Pharmaceuticals Inc. and was responsible for building OSI’s diabetes program in New York as well as Oxford, England. Prior to OSI Pharmaceuticals, Dr. Bergenhem, was employed by Novo Nordisk in Copenhagen, heading up a department focused on addressing dyslipideamia in type 2 diabetics. Dr. Bergenhem has extensive experience managing international collaborative programs, in the Novo Nordisk - Boehringer Ingelheim collaboration, as well as scientific manager of the OSI - Tanabe Seiyaku CO., Ltd. programs. Dr. Bergenhem holds a BS degree in Chemistry from Linkoping University, Sweden, and a Ph.D. in Biochemistry from Umeaa University, Sweden. He has completed postdoctoral work at University of Michigan in Molecular Biology and Human Genetics, where he also spent three years at the School of Medicine as Research Investigator at the Institute of Gerontology and at the Department of Biological Chemistry.
Gerri Waloga, Ph.D. Dr. Waloga is a founder of AdipoGenix and vice president. Previously, she was an Associate Professor of Physiology at Boston University School of Medicine where she had 14 years of experience as an independent investigator. Dr. Waloga is currently an Adjunct Associate Research Professor of Biochemistry. She has received numerous research grants and awards from the NIH. Dr. Waloga received her B.A. in biology at Northwestern University, her Ph.D. at Purdue University in biology and biophysics and completed post-graduate studies at Harvard University.